SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

002399

CNE100000P02

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.22 ^CNY	+0.33%		+2.56%	-21.40%

Apr. 02	Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane	MT
Apr. 02	Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd	CI

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SEHK:9989) dropped from FTSE All-World Index

March 17, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SEHK:9989) dropped from FTSE All-World Index (USD)

Latest news about Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane	Apr. 02	MT
Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd	Apr. 02	CI
Shenzhen Hepalink Pharmaceutical Widens 2023 Loss as Revenue Drops 24%	Apr. 01	MT
Shenzhen Techdow Medicine Co., Ltd., Wholly-Owned Subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Exarane Obtains Approval from New Zealand Medicines and Medical Devices Safety Authority	Mar. 28	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces No Final Dividend for the Year Ended 31 December 2023	Mar. 28	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SEHK:9989) dropped from FTSE All-World Index	Mar. 17	CI
Hepalink Pharmaceutical Gets Lifeline from Controlling Shareholder	Mar. 15	MT
Shenzhen Hepalink Forecasts Loss in 2023; Shares Slide 4%	Jan. 31	MT
Shenzhen Hepalink Flags Provisions of Up to 950 Million Yuan; Shares Fall 4%	Jan. 31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	Jan. 30	CI
Hepalink Faces Regulatory Scrutiny After 12 Million Euro Telecom Fraud; Hong Kong Shares Down 3%	Jan. 15	MT
Hepalink Pharma Unit Hit by 11.7 Million Euro Telecom Fraud	Jan. 15	MT
Hepalink Pharma Associate HighTide Therapeutics to Debut in Hong Kong on Friday	Dec. 18	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SZSE:002399) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SZSE:002399) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Hepalink Pharmaceutical's Profit Drops 86% in Q3; Shares Slump 4%	23-10-31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Hepalink Pharmaceutical's H1 Attributable Profit Plunges on Higher Share of Losses from Associates	23-08-31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen Juan	23-08-21	CI
Shenzhen Hepalink Pharmaceutical’s H1 Profit to Fall By Up to 81%	23-07-17	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023	23-07-11	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022	23-05-23	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announce Payment of Dividend on H Shares for the Year Ended December 31, 2022, Payable on May 31, 2023	23-05-22	CI

Chart Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

More charts

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Companyâs main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

9.22 CNY

Average target price

6.4 CNY

Spread / Average Target

-30.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	-21.40%	1.68B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.94%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+12.06%	13.64B
ZYDUS LIFESCIENCES LIMITED	+38.81%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals